Terms: = Pancreatic cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1
109 results:
1. K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract] [Full Text] [Related]
2. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.
Chen WY; Hu YH; Tsai YH; Hang JF; Tan PH; Chen CJ
Histopathology; 2024 Feb; 84(3):550-555. PubMed ID: 37983855
[TBL] [Abstract] [Full Text] [Related]
3. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
4.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract] [Full Text] [Related]
5. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
6. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract] [Full Text] [Related]
7. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
[TBL] [Abstract] [Full Text] [Related]
8. Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.
Gurav M; Epari S; Gogte P; Pai T; Deshpande G; Karnik N; Shetty O; Desai S
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7413-7425. PubMed ID: 36935431
[TBL] [Abstract] [Full Text] [Related]
9. Lipid raft protein flotillin-1 is important for the interaction between SOS1 and H-Ras/K-Ras, leading to Ras activation.
Jin H; Koh M; Lim H; Yong HY; Kim ES; Kim SY; Kim K; Jung J; Ryu WJ; Choi KY; Moon A
Int J Cancer; 2023 May; 152(9):1933-1946. PubMed ID: 36691829
[TBL] [Abstract] [Full Text] [Related]
10. Strategies for Targeting KRAS: A Challenging Drug Target.
Wadood A; Ajmal A; Rehman AU
Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
[TBL] [Abstract] [Full Text] [Related]
11. Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity.
Chen J; Li Z; Jia X; Song W; Wu H; Zhu H; Xuan Z; Du Y; Zhu X; Song G; Dong H; Bian S; Wang S; Zhao Y; Xie H; Zheng S; Song P
Oncogene; 2022 May; 41(22):3118-3130. PubMed ID: 35477750
[TBL] [Abstract] [Full Text] [Related]
12. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.
Shetu SA; Bandyopadhyay D
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409064
[TBL] [Abstract] [Full Text] [Related]
13. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
14. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
15. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract] [Full Text] [Related]
16. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
17. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract] [Full Text] [Related]
18. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
[TBL] [Abstract] [Full Text] [Related]
19. Ras sumoylation in cell signaling and transformation.
Dai W; Xie S; Chen C; Choi BH
Semin Cancer Biol; 2021 Nov; 76():301-309. PubMed ID: 33812985
[TBL] [Abstract] [Full Text] [Related]
20. A mucinous cystic neoplasm of the pancreas containing an undifferentiated carcinoma component and harboring the nras driver mutation.
Hisanaga E; Sano T; Yoshida Y; Ishii N; Shirabe K; Ikota H
Clin J Gastroenterol; 2021 Jun; 14(3):910-917. PubMed ID: 33710503
[TBL] [Abstract] [Full Text] [Related]
[Next]
